SCLX Stock Overview
Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Scilex Holding Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.15 |
52 Week High | US$8.30 |
52 Week Low | US$0.73 |
Beta | 0.92 |
1 Month Change | 20.87% |
3 Month Change | -33.91% |
1 Year Change | -83.24% |
3 Year Change | -88.44% |
5 Year Change | n/a |
Change since IPO | -88.32% |
Recent News & Updates
Recent updates
It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks
Apr 24Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues
Feb 28Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)
Dec 21Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings
May 06Shareholder Returns
SCLX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 40.5% | 1.9% | 1.2% |
1Y | -83.2% | 16.7% | 27.7% |
Return vs Industry: SCLX underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: SCLX underperformed the US Market which returned 27.7% over the past year.
Price Volatility
SCLX volatility | |
---|---|
SCLX Average Weekly Movement | 20.1% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SCLX's share price has been volatile over the past 3 months.
Volatility Over Time: SCLX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 106 | Jaisim Shah | www.scilexholding.com |
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia.
Scilex Holding Company Fundamentals Summary
SCLX fundamental statistics | |
---|---|
Market cap | US$134.44m |
Earnings (TTM) | -US$160.60m |
Revenue (TTM) | US$47.05m |
3.0x
P/S Ratio-0.9x
P/E RatioIs SCLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SCLX income statement (TTM) | |
---|---|
Revenue | US$47.05m |
Cost of Revenue | US$15.93m |
Gross Profit | US$31.12m |
Other Expenses | US$191.72m |
Earnings | -US$160.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.33 |
Gross Margin | 66.14% |
Net Profit Margin | -341.38% |
Debt/Equity Ratio | -57.6% |
How did SCLX perform over the long term?
See historical performance and comparison